Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
2.360
-0.070 (-2.88%)
Feb 21, 2025, 4:00 PM EST - Market closed
Tango Therapeutics Employees
Tango Therapeutics had 140 employees as of December 31, 2023. The number of employees increased by 30 or 27.27% compared to the previous year.
Employees
140
Change (1Y)
30
Growth (1Y)
27.27%
Revenue / Employee
$309,879
Profits / Employee
-$881,393
Market Cap
253.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 140 | 30 | 27.27% |
| Dec 31, 2022 | 110 | 19 | 20.88% |
| Dec 31, 2021 | 91 | 14 | 18.18% |
| Dec 31, 2020 | 77 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
TNGX News
- 23 days ago - Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - GlobeNewsWire
- 4 weeks ago - Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
- 2 months ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 3 months ago - Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 3 months ago - Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - Business Wire
- 5 months ago - Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data - Seeking Alpha
- 6 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire